STOCK TITAN

Stereotaxis (STXS) Stock Price, News & Analysis

STXS NYSE
Published by Stock Titan Data refreshed

Why is STXS Stock Down Today?

4.18% after hours
12 alerts
15m delay

Stereotaxis, Inc. (STXS) reported higher third-quarter revenue in its November 16 quarterly report, published two days before today. The report also showed net loss of $6.482 million, versus $6.463 million a year earlier, and nine-month revenue of $22.886 million, versus $23.735 million.

AI-generated explanation by Rhea-AI, written on at . How Rhea-AI works. Not financial advice.

Price Move History

Daily moves over 5%
33 252 sessions, November 18, 2025 to November 18, 2026
Largest daily move
+13.5% close of November 4, 2026
1-year change
-58.7% closing prices, November 18, 2025 to November 18, 2026
1-month change
-6.3% closing prices, October 16, 2026 to November 18, 2026

Company Description

Stereotaxis, Inc. (NYSE: STXS) operates in the surgical and medical instrument manufacturing industry with a focus on surgical robotics for minimally invasive endovascular intervention. According to the company’s public statements, Stereotaxis describes itself as a pioneer and global leader in innovative surgical robotics that support procedures in the interventional laboratory. Its stated mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions that assist physicians in treating patients with enhanced precision and safety, while improving workflow, connectivity, and intelligence in the operating room and cath lab.

The company’s technology is centered on Robotic Magnetic Navigation, which uses computer-controlled magnetic fields to navigate interventional devices inside the body. Stereotaxis reports that its technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and other regions. These procedures are typically minimally invasive and endovascular, meaning they are performed within blood vessels using catheters and related instruments rather than open surgery.

Core business and product ecosystem

Based on company disclosures, Stereotaxis’ business combines capital robotic systems, disposable devices, and digital and information solutions for the interventional lab. Earlier descriptions note that revenue is generated from systems, disposables, royalty, and sublease streams, with a majority of revenue derived from disposables, service, and accessories. More recent communications emphasize a growing portfolio of proprietary robotically navigated devices and digital cath lab technologies.

The company highlights several key technology families in its public news releases:

  • Robotic Magnetic Navigation systems, including the Genesis and GenesisX platforms, which are designed to bring robotic precision and safety to cardiac ablation and other endovascular procedures.
  • MAGiC, a robotically navigated magnetic interventional ablation catheter intended for cardiac ablation procedures to treat heart arrhythmias, particularly in complex and underserved patient populations where conventional manual catheter navigation is limited.
  • MAGiC Sweep, described as the first robotically navigated high-density electrophysiology mapping catheter, used to create detailed maps of complex cardiac anatomy during arrhythmia diagnosis and treatment.
  • Synchrony, a system designed to digitize and modernize the interventional cath lab by consolidating viewing and control of disparate systems onto a single large 4K display and enabling streamlined workflows and custom layouts.
  • SynX, a cloud-based application associated with Synchrony that provides secure remote connectivity, collaboration, recording, and monitoring of the cath lab, and is described as HIPAA and GDPR compliant.

Through these technologies, Stereotaxis positions itself at the intersection of robotic systems, interventional catheters, and digital lab integration. The company’s communications emphasize that its solutions are intended to expand access to minimally invasive therapy, support complex electrophysiology procedures, and enhance lab productivity.

Clinical focus and use cases

Company materials indicate that Stereotaxis’ technology is primarily used in cardiac electrophysiology and other endovascular interventions. Robotic Magnetic Navigation is described as playing a central role in the treatment of complex arrhythmias, including procedures for patients with congenital heart disease and complex heart rhythm disorders. The MAGiC ablation catheter is indicated for cardiac electrophysiological mapping, delivering diagnostic pacing stimuli, and creating endocardial lesions to treat specific supraventricular tachycardias in patients with congenital heart disease where conventional access is limited.

Public case examples include use of the Genesis system and MAGiC catheter at leading medical centers, and the first commercial robotic high-density mapping procedures with MAGiC Sweep in the United States. These examples illustrate how the company’s robotic systems and catheters are combined in clinical practice to navigate within the heart, create detailed electrical maps, and perform ablation therapy for arrhythmias.

Digital cath lab and remote connectivity

Beyond robotics and catheters, Stereotaxis has disclosed efforts to modernize the interventional cath lab through digital and cloud-based tools. Synchrony is described as consolidating video streams from multiple systems with ultra-high-definition visualization and low latency, aiming to provide an enhanced procedure experience and a decluttered environment. The associated SynX application enables remote connectivity and collaboration, including secure viewing, recording, and monitoring of procedures.

The company notes that Synchrony and SynX are engineered as foundational platforms for future innovations, with an architecture that can support future applications and the use of artificial intelligence for clinical insights, automation, and safety. Public statements also link these digital tools to broader “digital surgery” efforts, including support for future remote long-distance procedures and automated catheter navigation.

Regulatory and geographic footprint

Stereotaxis’ communications reference multiple regulatory milestones. The company has announced U.S. Food and Drug Administration (FDA) clearance for its GenesisX robotic system and FDA approval for the MAGiC Magnetic Interventional Ablation Catheter. It has also reported obtaining CE Mark in Europe for the Synchrony system and submitting a 510(k) application to the FDA for Synchrony. These regulatory clearances and submissions underscore the company’s focus on bringing new robotic and digital technologies into clinical use in major healthcare markets.

The company reports that its technology has been used to treat patients across the United States, Europe, Asia, and elsewhere. Examples in public releases include installations and procedures at hospitals in Europe and the United States, indicating adoption of Stereotaxis systems in multiple regions.

Capital markets and corporate structure

Stereotaxis, Inc. is incorporated in Delaware and its common stock trades on the New York Stock Exchange under the symbol STXS. The company has filed current reports on Form 8-K describing, among other matters, earnings press releases and a Sales Agreement with Roth Capital Partners, LLC that allows for at-the-market offerings of common stock under an effective shelf registration statement on Form S-3. According to these filings, potential proceeds from such offerings are intended for working capital, research and development, and other general corporate purposes, including commercialization of its innovation pipeline.

Financial disclosures in earnings releases and SEC filings detail revenue contributions from systems and from disposables, service, and accessories, as well as information on operating expenses, cash balances, and other financial metrics. These figures are time-specific and are best reviewed directly in the company’s periodic and current reports for up-to-date information.

Position within surgical and medical instrument manufacturing

Within the broader manufacturing sector, Stereotaxis is classified in surgical and medical instrument manufacturing, with a specialization in robotic systems and related devices for minimally invasive endovascular procedures. Its public statements emphasize a focus on electrophysiology and cardiovascular care, combining hardware, disposable catheters, and software to support interventional labs.

Investors and clinicians evaluating STXS stock or Stereotaxis’ technologies can look to the company’s news releases and SEC filings for details on product clearances, collaborations, commercialization progress, and financial performance. Because the company frequently references ongoing regulatory reviews, product launches, and clinical collaborations, those primary sources provide the most current view of its activities and strategy.

Stock Performance

$0.9066
-4.18%
-0.0395
After hoursChange vs the $0.9461 closeLast updated: at
-58.7%
Performance 1 year
$91.4M

Stereotaxis (STXS) closed at $0.9461 on November 18, 2026. Over the past 12 months, the price has lost 58.7%.

See what a $1,000 investment in STXS would be worth today

Average down calculator for STXS

STXS Metrics & Rankings

Price returns through November 18, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Insider Radar

Net Buyers
90-Day Summary
13,300
Shares Bought
0
Shares Sold
2
Transactions
Most Recent Transaction
Isaac Paul J (Director) bought 300 shares held indirectly @ $0.8000 on November 17, 2026

Insider buying activity at Stereotaxis over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Stereotaxis generated $32.4M in revenue in FY2025, retaining a 52.7% gross margin, operating income reached -$22.1M (-68.3% operating margin), and net income was -$21.6M, reflecting a -66.8% net profit margin. Diluted earnings per share stood at -$0.25. The company generated -$13.7M in operating cash flow. The current ratio was 1.51, measuring current assets divided by current liabilities.

$32.4M
Revenue (FY2025)
-$21.6M
Net Income (FY2025)
-$13.7M
Operating Cash Flow

Upcoming Events

NOV
10
November 10, 2029 Financial

Note maturity

Maturity of convertible notes issued at initial closing; 10% interest accrued and due at maturity three years after closing.

Stereotaxis has 1 upcoming scheduled event. The next event, "Note maturity", is scheduled for November 10, 2029 (in 1088 days). It is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the STXS stock price.

Short Interest History

Last 12 Months

Short interest in Stereotaxis (STXS) currently stands at 5.6 million shares, down 7.3% from the previous reporting period, representing 6.7% of the float. Since November 2025, short interest has increased by 84.2%.

Days to Cover History

Last 12 Months

Days to cover for Stereotaxis (STXS) currently stands at 8.4 days, down 17.5% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 38.4%. Across the settlements charted above, it has ranged from 2.5 to 11.8 days.

STXS Company Profile & Sector Positioning

Stereotaxis (STXS) operates in the Medical Instruments & Supplies industry within the broader Healthcare sector and is listed on the NYSE.

Investors comparing STXS often look at related companies in the same sector, including Precision Optics Corporation, Inc. (POCI), KORU Medical Systems, Inc. (KRMD), Anbio Biotechnology (NNNN), Pro-Dex Inc New (PDEX), and Utah Medical Products Inc (UTMD). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate STXS's relative position within its industry.

Frequently Asked Questions

The current stock price of Stereotaxis (STXS) is $0.9066 in after-hours trading as of November 18, 2026.

The market cap of Stereotaxis (STXS) is approximately $91.4M. Learn more about what market capitalization means .

The FY2025 revenue of Stereotaxis (STXS) is $32.4M, from its most recent completed fiscal year.

The FY2025 net income of Stereotaxis (STXS) is -$21.6M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Stereotaxis (STXS) is -$0.25 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Stereotaxis (STXS) is -$13.7M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Stereotaxis (STXS) is -66.8% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Stereotaxis (STXS) is -68.3% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Stereotaxis (STXS) is 52.7% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Stereotaxis (STXS), current assets divided by current liabilities, was 1.51 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Stereotaxis (STXS) is $17.1M for FY2025, its most recent completed fiscal year.

The operating income of Stereotaxis (STXS) is -$22.1M for FY2025, its most recent completed fiscal year. Learn about operating income.

Stereotaxis, Inc. focuses on surgical robotics for minimally invasive endovascular intervention. According to its public statements, the company’s mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory, with an emphasis on robotic precision, safety, and improved workflow in the operating room and cath lab.

Stereotaxis is classified in surgical and medical instrument manufacturing within the broader manufacturing sector. Its activities center on robotic systems, catheters, and digital solutions used in interventional medicine, particularly cardiac electrophysiology and other minimally invasive endovascular procedures.

Earlier company descriptions state that Stereotaxis generates revenue from systems, disposables, royalty, and sublease streams, with a majority of revenue coming from disposables, service, and accessories. More recent disclosures also highlight contributions from proprietary robotically navigated devices and recurring revenue associated with these products.

Robotic Magnetic Navigation, as described by Stereotaxis, uses highly precise computer-controlled magnetic fields to navigate catheters during minimally invasive procedures. This approach is intended to provide maneuverability, precision, and stability that may not be possible with traditional manually steered catheters, particularly in complex cardiac arrhythmia procedures.

Public company communications highlight several technologies, including Genesis and GenesisX Robotic Magnetic Navigation systems, the MAGiC Magnetic Interventional Ablation Catheter, the MAGiC Sweep high-density electrophysiology mapping catheter, the Synchrony digital cath lab system, and the SynX cloud-based application for secure remote connectivity and collaboration in the cath lab.

Stereotaxis reports that its robotic systems and catheters are used in cardiac ablation and electrophysiology procedures to treat arrhythmias. The technology supports cardiac electrophysiological mapping, diagnostic pacing, and creation of endocardial lesions. Company examples include use in complex arrhythmia cases and in patients with congenital heart disease where conventional manual catheter navigation is limited.

According to the company, Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. Public news releases reference installations and procedures at hospitals in Europe and the United States, indicating a geographic footprint that spans multiple regions.

Stereotaxis has announced U.S. FDA 510(k) clearance for its GenesisX robotic system and U.S. FDA approval for the MAGiC Magnetic Interventional Ablation Catheter. It has also reported obtaining CE Mark in Europe for the Synchrony system and submitting a 510(k) application to the FDA for Synchrony. These regulatory events are described in the company’s news releases.

Stereotaxis, Inc. trades on the New York Stock Exchange under the ticker symbol STXS. This symbol is referenced in the company’s news releases and SEC filings.

In a Form 8-K, Stereotaxis reported entering into a Sales Agreement with Roth Capital Partners, LLC, allowing the company to sell shares of its common stock from time to time under an effective shelf registration statement on Form S-3. The company stated that net proceeds are intended for working capital, research and development, and other general corporate purposes, including accelerated commercialization of its innovation pipeline.